Cargando…
Prognostic bioindicators in severe COVID-19 patients
BACKGROUND: Severe acute respiratory syndrome caused by novel coronavirus 2 (SARS-CoV-2) emerged in Wuhan (China) in December 2019. Here we evaluated a panel of biomarkers to phenotype patients and to define the role of immuno-inflammatory mediators as biomarkers of severity. MATERIALS AND METHODS:...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Ltd.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7843114/ https://www.ncbi.nlm.nih.gov/pubmed/33548798 http://dx.doi.org/10.1016/j.cyto.2021.155455 |
_version_ | 1783644079619309568 |
---|---|
author | Bergantini, L. Bargagli, E. d'Alessandro, M. Refini, R.M. Cameli, P. Galasso, L. Scapellato, C. Montagnani, F. Scolletta, S. Franchi, F. Valente, S. Bennett, D. Sebastiani, G. Frediani, B. Dotta, F. |
author_facet | Bergantini, L. Bargagli, E. d'Alessandro, M. Refini, R.M. Cameli, P. Galasso, L. Scapellato, C. Montagnani, F. Scolletta, S. Franchi, F. Valente, S. Bennett, D. Sebastiani, G. Frediani, B. Dotta, F. |
author_sort | Bergantini, L. |
collection | PubMed |
description | BACKGROUND: Severe acute respiratory syndrome caused by novel coronavirus 2 (SARS-CoV-2) emerged in Wuhan (China) in December 2019. Here we evaluated a panel of biomarkers to phenotype patients and to define the role of immuno-inflammatory mediators as biomarkers of severity. MATERIALS AND METHODS: Serum samples were obtained from 24 COVID-19 patients on admission to hospital, before any treatment or infusion of intravenous steroids or invasive ventilation. KL-6 IL-6 and C-peptide were measured by chemiluminescent enzyme immunoassay. IL-6 assay was validated for accuracy and precision. The validity of variables used to distinguish severe from mild-to-moderate patients was assessed by areas under curves (AUC) of the receiver operating characteristic (ROC) and logistic regression was performed to combine parameters of the two groups. RESULTS: In the severe group, IL-6, CRP and KL-6 concentrations were significantly higher than in mild-to-moderate patients. KL-6, IL-6 and CRP concentrations were directly correlated with each other. ROC curve analysis of the logistic regression model including IL-6, KL-6 and CRP showed the best performance with an AUC of 0.95. CONCLUSIONS: Besides corroborating previous reports of over-expression of IL-6 in severe COVID-19 patients requiring mechanical ventilation, analytical determination of other mediators showed that IL-6 concentrations were correlated with those of KL-6 and CRP. The combination of these three prognostic bioindicators made it possible to distinguish severe COVID-19 patients with poor prognosis from mild-to-moderate patients. |
format | Online Article Text |
id | pubmed-7843114 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Elsevier Ltd. |
record_format | MEDLINE/PubMed |
spelling | pubmed-78431142021-01-29 Prognostic bioindicators in severe COVID-19 patients Bergantini, L. Bargagli, E. d'Alessandro, M. Refini, R.M. Cameli, P. Galasso, L. Scapellato, C. Montagnani, F. Scolletta, S. Franchi, F. Valente, S. Bennett, D. Sebastiani, G. Frediani, B. Dotta, F. Cytokine Article BACKGROUND: Severe acute respiratory syndrome caused by novel coronavirus 2 (SARS-CoV-2) emerged in Wuhan (China) in December 2019. Here we evaluated a panel of biomarkers to phenotype patients and to define the role of immuno-inflammatory mediators as biomarkers of severity. MATERIALS AND METHODS: Serum samples were obtained from 24 COVID-19 patients on admission to hospital, before any treatment or infusion of intravenous steroids or invasive ventilation. KL-6 IL-6 and C-peptide were measured by chemiluminescent enzyme immunoassay. IL-6 assay was validated for accuracy and precision. The validity of variables used to distinguish severe from mild-to-moderate patients was assessed by areas under curves (AUC) of the receiver operating characteristic (ROC) and logistic regression was performed to combine parameters of the two groups. RESULTS: In the severe group, IL-6, CRP and KL-6 concentrations were significantly higher than in mild-to-moderate patients. KL-6, IL-6 and CRP concentrations were directly correlated with each other. ROC curve analysis of the logistic regression model including IL-6, KL-6 and CRP showed the best performance with an AUC of 0.95. CONCLUSIONS: Besides corroborating previous reports of over-expression of IL-6 in severe COVID-19 patients requiring mechanical ventilation, analytical determination of other mediators showed that IL-6 concentrations were correlated with those of KL-6 and CRP. The combination of these three prognostic bioindicators made it possible to distinguish severe COVID-19 patients with poor prognosis from mild-to-moderate patients. Elsevier Ltd. 2021-05 2021-01-28 /pmc/articles/PMC7843114/ /pubmed/33548798 http://dx.doi.org/10.1016/j.cyto.2021.155455 Text en © 2021 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Article Bergantini, L. Bargagli, E. d'Alessandro, M. Refini, R.M. Cameli, P. Galasso, L. Scapellato, C. Montagnani, F. Scolletta, S. Franchi, F. Valente, S. Bennett, D. Sebastiani, G. Frediani, B. Dotta, F. Prognostic bioindicators in severe COVID-19 patients |
title | Prognostic bioindicators in severe COVID-19 patients |
title_full | Prognostic bioindicators in severe COVID-19 patients |
title_fullStr | Prognostic bioindicators in severe COVID-19 patients |
title_full_unstemmed | Prognostic bioindicators in severe COVID-19 patients |
title_short | Prognostic bioindicators in severe COVID-19 patients |
title_sort | prognostic bioindicators in severe covid-19 patients |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7843114/ https://www.ncbi.nlm.nih.gov/pubmed/33548798 http://dx.doi.org/10.1016/j.cyto.2021.155455 |
work_keys_str_mv | AT bergantinil prognosticbioindicatorsinseverecovid19patients AT bargaglie prognosticbioindicatorsinseverecovid19patients AT dalessandrom prognosticbioindicatorsinseverecovid19patients AT refinirm prognosticbioindicatorsinseverecovid19patients AT camelip prognosticbioindicatorsinseverecovid19patients AT galassol prognosticbioindicatorsinseverecovid19patients AT scapellatoc prognosticbioindicatorsinseverecovid19patients AT montagnanif prognosticbioindicatorsinseverecovid19patients AT scollettas prognosticbioindicatorsinseverecovid19patients AT franchif prognosticbioindicatorsinseverecovid19patients AT valentes prognosticbioindicatorsinseverecovid19patients AT bennettd prognosticbioindicatorsinseverecovid19patients AT sebastianig prognosticbioindicatorsinseverecovid19patients AT fredianib prognosticbioindicatorsinseverecovid19patients AT dottaf prognosticbioindicatorsinseverecovid19patients |